Jupiter Life Line Hospitals Limited has informed the Exchange that Board of Directors at its meeting held on May 09, 2025, recommended Final Dividend of Re. 1 per equity share.
JLHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jupiter Life Line Hospitals' Board approved audited standalone and consolidated financial results for FY ended March 31, 2025, with statutory auditors issuing an unmodified opinion. The Board recommended a final dividend of Re. 1 per equity share (10% on face value of Rs. 10) for FY25, subject to shareholder approval at the upcoming AGM. The Board approved the appointment of Dr. Ankit Thakker as Joint Managing Director and CEO for five years effective July 11, 2025, and the scheme of amalgamation of wholly-owned subsidiary Medulla Healthcare with the company. Other approvals include Mr. Sivasis Sen as new CFO from May 12, 2025, M/s. KKC & Associates LLP as the new statutory auditor for the next 5-year term, M/s. Yogesh Sharma & Co. as secretarial auditors, and several senior management/designation changes. Consolidated revenue from operations grew to ~Rs. 10,734 million (from ~Rs. 9,001 million in FY24) and consolidated profit grew to ~Rs. 1,766 million (from ~Rs. 1,339 million in FY24).
Shareholders will receive a modest final dividend of Rs. 1 per share if approved at the AGM. The clean audit opinion, solid profit growth, new leadership appointments, and merger of a wholly-owned subsidiary point to stable governance and a routine internal restructuring rather than any negative event.